Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02483325
Other study ID # BX-PK-IPC 2013-016
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2014
Est. completion date March 2020

Study information

Verified date January 2019
Source Institut Paoli-Calmettes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Determine the efficiency of a myéloablative conditioning associating Fludarabine, Thymoglobuline, and intravenous Busulfan with adapted dose, according to a pharmacokinetics realized in the first day of administration (or J-6 of the conditioning) of the busulfan, in preparation for a allogenic transplant family or not family compatible HLA.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date March 2020
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 55 Years and older
Eligibility Inclusion Criteria :

- Informed consent signed,

- Patient affiliated to a social security system or benefiting from such a system,

- Related HLA identical donor or unrelated HLA identical donor :

all patients aged > 55 years with hematological malignancy and deemed eligible for an allogeneic transplant from a geno-identical donor and pheno-identical 10/10

- the basic pathology should be considered "chemo-sensitive" complete or partial remission (CR, PR) or stable disease

Exclusion Criteria :

- Pregnant or lactating woman or without contraception (for child bearing potential women)

- Patient deprived of liberty or under supervision of a guardian

- Impossibility to undergo medical examinations of the study for geographical, social or psychological reasons

- Usual contra-indications for allogenic transplant

- Aged < 55 years

- History of allogenic transplant

- Concomitant neoplastic disease

- Evolutive psychiatric disease

- HIV seropositivity or C hepatitis under treatment

- Women of childbearing age or man, in the absence of effective contraception during treatment and up to 12 months after treatment discontinuation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Allogeneic transplant conditioning
Allogeneic transplant

Locations

Country Name City State
France Institut Paoli Calmettes Marseille

Sponsors (2)

Lead Sponsor Collaborator
Institut Paoli-Calmettes Agence de La Biomédecine

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary rates progression free survival 2 years Time to progression or death
Secondary Plasmatic concentration of Busulfan Time from inclusion until Day -1 before allogenic transplantation
See also
  Status Clinical Trial Phase
Recruiting NCT02241031 - Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia Phase 2/Phase 3
Recruiting NCT02240992 - MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Phase 2/Phase 3
Recruiting NCT05041933 - Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting
Completed NCT00675038 - Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload N/A
Active, not recruiting NCT03745287 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease Phase 2/Phase 3
Recruiting NCT05505760 - Testing Content Delivery Models for MomConnect N/A
Recruiting NCT00884364 - Exercise During Chemotherapy for Patients With Hematological Malignancies Phase 3
Recruiting NCT01160952 - Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation Phase 2
Completed NCT00892502 - Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? N/A
Active, not recruiting NCT00838643 - Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) N/A
Recruiting NCT05329649 - Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) Phase 3
Not yet recruiting NCT06281496 - AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Enrolling by invitation NCT06277479 - Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study
Completed NCT00956358 - Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation N/A
Completed NCT01344681 - Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases Phase 2
Recruiting NCT02083718 - Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function Phase 2
Recruiting NCT02083731 - MSC for Treatment of CMV Infection Phase 2
Recruiting NCT01763086 - Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant Phase 2
Recruiting NCT01763099 - Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Phase 2